Recent

% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

  • kgrichard5 kgrichard5 Apr 12, 2013 9:21 AM Flag

    I am doing this board a favor New thread for "Cur Treatments

    &Test Result dates. The below thread was too long. This is a great post so lets keep it efficient and reduce the mess:
    From CUR's Home Website....Check this out then check out CUR's Home Website for much more.

    About Cell Therapy Pharmaceuticals . ShareThis Contact Us
    Home
    Patients
    Investors
    News
    CEO Blog
    Cell Therapy Treatments in Development
    ALS
    Ongoing Phase I safety clinical trial at Emory University Hospital completes final cohort transplanting Neuralstem’s NSI-566 cells in both the cervical and lumbar regions of the spinal cord in August 2012; the trial ends six months after that last surgery. In Mexico City, ALS Phase I / II trial expected to commence in 1Q2013. More

    Ischemic Stroke
    Phase I / II trial for ischemic stroke expected to be underway in first quarter of 2013 in collaboration with BaYi Brain Hospital in Beijing. More

    Spinal Cord Injury
    FDA approved Phase I safety trial transplanting NSI-566 into the T2-T12 lumbar regions of chronic SCI patients, in January 2013. Acute SCI trial expected to commence in Seoul, South Korea in mid-2013. More

    Glioblastoma (Brain Cancer)
    Preclinical phase in collaboration with Loma Linda University as part of a U.S. Department of Defense-funded research program, entitled “Research to Treat Cancerous Brain Tumors with Neural Stem Cells.”

    Multiple Sclerosis
    Preclinical phase with NSI-566. Further clinical development on multiple sclerosis application pending NSI-566 ALS ongoing trial.

    Optic Neuritis
    Preclinical phase with NSI-566. Further clinical development on optic neuritis application pending NSI-566 ALS ongoing trial.

    Alzheimer’s Disease
    Preclinical phase with NSI-566. Further clinical development on Alzheimer’s disease application pending NSI-566 ALS ongoing trial.

    Traumatic Brain Injury
    Preclinical phase with NSI-566. Further clinical development on traumatic brain injury application pending NSI-566 ALS ongoing trial.

    Peripheral Nerve Injury
    Preclinical phase with NSI-566. Further clinical development on peripheral nerve injury application pending NSI-566 ALS ongoing trial.

    Diabetic Neuropathy
    Preclinical phase with NSI-566. Further clinical development on diabetic neuropathy application pending NSI-566 ALS ongoing trial.

    Lysosomal Diseases
    Preclinical phase with NSI-566. Further clinical development on lysosomal diseases application pending NSI-566 ALS ongoing trial.

    Parkinson’s Disease
    Preclinical phase with NSI-566. Further clinical development on Parkinson’s disease application pending NSI-566 ALS ongoing trial.

    Huntington’s Disease
    Preclinical phase with NSI-566. Further clinical development on Huntington’s disease application pending NSI-566 ALS ongoing trial.

    Cerebral Palsy
    Preclinical phase with NSI-566. Further clinical development on cerebral palsy application pending NSI-566 ALS ongoing trial.

    Ischemic Spastic Paraplegia
    Preclinical phase with the University of California at San Diego. Lead collaborator, Dr. Martin Marsala, PhD authored a peer-reviewed paper on study results. More

    Drug Treatments in Development

    Major Depressive Disorder
    Ongoing Phase I trial for neurogenic small molecule drug, NSI-189 advances to Phase Ib in June 2012, testing the safety and tolerability of escalating doses of NSI-189 for 28 daily administrations in 24 depression patients. Phase Ib is expected to be completed in 1Q13. More

    Alzheimer’s Disease
    Preclinical phase with NSI-189, which was originally developed to address cognitive indications. Further clinical development on Alzheimer’s disease application pending NSI-189 major depressive disorder ongoing trial.

    Cognitive complication due to Diabetes
    Preclinical phase with NSI-189. Further clinical development on cognitive complication due to diabetes application pending NSI-189 major depressive disorder ongoing trial.

    Stroke
    Preclinical phase with NSI-189. Further clinical development on stroke application pending NSI-189 major depressive disorder ongoing trial.

    Traumatic Brain Injury
    Preclinical phase with NSI-189. Further clinical development on traumatic brain injury application pending NSI-189 major depressive disorder ongoing trial.

    Post-Traumatic Stress Disorder
    Preclinical phase with NSI-189. Further clinical development on PTSD application pending NSI-189 major depressive disorder ongoing trial.

    CTE - Chronic Traumatic Encephalopathy
    Preclinical phase with NSI-189. Further clinical development on CTE application pending NSI-189 major depressive disorder ongoing trial.

    Neurodegeneration
    Preclinical phase with NSI-189. Further clinical development on neurodegeneration application pending NSI-189 major depressive disorder ongoing trial.

    Anti-Aging (Nootropic)
    Preclinical phase with NSI-189. Further clinical development on anti-aging (nootropic) application pending NSI-189 major depressive disorder ongoing trial.

    Privacy and Terms ©Neuralstem, Inc. 2013 Less

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CUR
1.94-0.06(-3.00%)Apr 24 4:00 PMEDT